Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 1.00 |
| ▸ | PRKACA | P17612 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | PRKX | P51817 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372951 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL6969527 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL30069136 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29378010 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL124161 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29677841 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2456059 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL507871 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2461354 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29781011 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372673-B1 | METHOD FOR PRODUCING CEREBELLAR PROGENITOR TISSUE | RIKEN (JP) | 2023-12-13 | — | — | EP | claimed |
| US-10781420-B2 | Method for producing cerebellar progenitor tissue | RIKEN (JP) | 2020-09-22 | — | — | US | claimed |
| US-9980972-B2 | Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2018-05-29 | — | — | US | claimed |
| EP-2825175-B1 | RHO KINASE INHIBITORS FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin (DE) | 2017-07-26 | — | — | EP | claimed |
| WO-2009116840-A2 | CHEMICAL REAGENTS REGULATING STEM CELL FATE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2009-09-24 | — | — | WO | claimed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | claimed |
| US-20260028584-A1 | METHOD FOR EVALUATING AGGREGATION-SUPPRESSING ACTIVITY OR AGGREGATION-PROMOTING ACTIVITY ON AGGREGATING PROTEIN USING ORGANOID, AND METHOD FOR PRODUCING ORGANOID | KANEKA CORPORATION (JP) | 2026-01-29 | — | — | US | disclosed |
| US-12534705-B2 | Method for producing pluripotent stem cells | KANEKA CORPORATION (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-4338751-B1 | COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250250539-A1 | METHOD FOR EVALUATING ACTIVITY OF INHIBITING OR PROMOTING AGGREGATION OF AGGREGATING PROTEINS | KANEKA CORPORATION (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4597103-A1 | METHOD FOR ASSESSING COAGULATION INHIBITION ACTIVITY OR COAGULATION PROMOTION ACTIVITY AGAINST COAGULATIVE PROTEIN | Kaneka Corporation (JP) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025058089-A1 | AGENT FOR SUPPRESSING AMYLOID β AGGREGATION/DEPOSITION AND AGENT FOR SUPPRESSING/IMPROVING COGNITIVE DECLINE OF SUBJECT | 株式会社カネカ | 2025-03-20 | — | — | WO | disclosed |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| WO-2008015001-A1 | RHO/ROCK/P13/AKT KINASE INHIBITORS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PROTOZOAN PARASITES | UNIVERSITE PIERRE ET MARIE CURIE-PARIS VI (FR) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060052367-A1 | Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050245509-A1 | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins | SANTEN PHARMACECUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1568382-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1541151-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534705-B2 | Method for producing pluripotent stem cells | WNT3A, WNT1, CTNNBL1 | ROCK2 2693/4885ROCK1 2491/4885PRKACA 2594/4885 |
| US-20260028584-A1 | METHOD FOR EVALUATING AGGREGATION-SUPPRESSING ACTIVITY OR AGGREGATION-PROMOTING ACTIVITY ON AGGREGATING PROTEIN USING ORGANOID, AND METHOD FOR PRODUCING ORGANOID | TTR, IAPP, TPM4 | ROCK2 3149/4885ROCK1 3637/4885PRKACA 1470/4885 |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKACA 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.